ALPMY Overview
Upcoming Projects (ALPMY)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (ALPMY)
-
Examining the potential of Astellas’ fezolinetant as a treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.
Ticker: ALPMY
Executed On: Aug 31, 2022 at 06:00 PM EDT
Upcoming & Overdue Catalysts (ALPMY)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (ALPMY)
-
AstraZeneca and Astellas working with FibroGen in studies treating CKD anemia, with NDA expected in 2018
Tickers: FGEN, AZN, ALPMY
Occurred on: Oct 01, 2018 -
Cytokinetics Announces Start of Phase 1b Clinical Trial of CK-2127107 in Elderly Subjects With Limited Mobility
Tickers: CYTK, ALPMY
Occurred on: Jun 29, 2017 -
Astellas (ALPMY) and Ironwood (IRWD) Expect to Launch Linzess in Japan for the Treatment of Adults with IBS-C in the First Half of 2017
Tickers: IRWD, ALPMY
Occurred on: May 08, 2017 -
Amgen (AMGN) and Astellas Pharma (ALPMY) File Marketing Application in Japan for Romosozumab in Osteoporosis Patients at High Risk of Fracture
Tickers: AMGN, ALPMY
Occurred on: Dec 19, 2016 -
Medivation and Astellas Initiate Phase III Trial of Enzalutamide in Patients With Triple-Negative Breast Cancer
Tickers: MDVN, ALPMY
Occurred on: Jun 02, 2016 -
Phase 2 TERRAIN Trial of enzalutamide Compared to bicalutamide in Metastatic Castration-Resistant Prostate Cancer achieved its primary endpoint
Tickers: MDVN, TSE:4503, ALPMY
Occurred on: Jan 13, 2016
Strategic Initiatives (ALPMY)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
